Zoetis (ZTS) Acquisitions (2015 - 2022)

Zoetis (ZTS) posted quarterly Acquisitions of $215.0 million for Q3 2022, down 88.59% quarter-over-quarter from $1.9 billion in Q3 2018.

Zoetis (ZTS) Acquisitions (2015 - 2022) Analysis & Trends

Zoetis (ZTS) has reported Acquisitions for 5 consecutive years, with $215.0 million the latest figure, recorded in Q3 2022.

In Q3 2022, Acquisitions changed N/A year-over-year to $215.0 million; the TTM figure through Sep 2022 stood at $215.0 million (changed N/A YoY), while the FY2018 annual figure was $1.9 billion, changed N/A from the prior year.
Acquisitions fell to $215.0 million in Q3 2022 per ZTS's latest filing, from $1.9 billion in the prior quarter.
Across five years, Acquisitions topped out at $1.9 billion in Q3 2018 and bottomed at $215.0 million in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Haleon	43.89 Bn	42.93 Bn	-	-
2	Teva Pharmaceutical Industries	43.01 Bn	39.35 Bn	2.15 Bn	-
3	Zoetis	31.52 Bn	29.84 Bn	1.05 Bn	-
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	-
5	United Therapeutics	22.17 Bn	19.51 Bn	683.80 Mn	-
6	Viatris	18.73 Bn	17.85 Bn	1.46 Bn	-
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn	-
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	-
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-	-
10	Alkermes	8.12 Bn	7.46 Bn	397.90 Mn	-

Download Data